BioSpectator Reporter Jeongmin Jo
Combining stem cell application technology and pain control technology to jointly develop treatments for major spinal diseases notamment degenerative disc disease and spinal cord injury
CHA University Bundang CHA Hospital a annoncé le 18th that it a signé a business accord with RudaCure, a company developing treatments for douleur neuropathique, for the 'development of spinal disease regenerative thérapeutiques.'
Sur la base de this accord, Bundang CHA Hospital and RudaCure will combine Bundang CHA Hospital's stem cell application regenerative technology with RudaCure's pain control technology to pursue: ▲ development of new spinal disease treatments with pain control and regenerative effects ▲ conducting essais cliniques of jointly developed treatments at Bundang CHA Hospital ▲ new drug approval sur la base de joint essais cliniques ▲ joint transfert de technologie and développement de nouveaux médicaments for industrialization of spinal disease treatments.
Jaehua Kim, Director of Bundang CHA Hospital, a déclaré : "Grâce à cela accord between Bundang CHA Hospital, which has strengths in stem cell research for major spinal diseases tels que degenerative disc disease and spinal cord injury, and RudaCure, which specializes in traitement de la douleur développement de nouveaux médicaments, we look forward to creating cases of innovant treatment technology for spinal diseases."